302 related articles for article (PubMed ID: 26146802)
1. Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab era.
Mussetti A; Devlin SM; Castro-Malaspina HR; Barker JN; Giralt SA; Zelenetz AD; Sauter CS; Perales MA
Bone Marrow Transplant; 2015 Oct; 50(10):1293-1298. PubMed ID: 26146802
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
3. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
4. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
5. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study.
Sandoval-Sus JD; Faramand R; Chavez J; Puri S; Parra P; Sokol L; Kharfan-Dabaja MA; Shah B; Ayala E
Leuk Lymphoma; 2019 Feb; 60(2):309-316. PubMed ID: 29963932
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
[TBL] [Abstract][Full Text] [Related]
8. [Cytarabine and hematopoietic cell transplantation for mantle cell lymphoma. Analysis of 20 patients].
Campbell J; Hurtado S; Kutz C; Soto K; Ernst D
Rev Med Chil; 2019; 147(1):9-17. PubMed ID: 30848759
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
Dodero A; Patriarca F; Milone G; Sarina B; Miceli R; Iori A; Barretta F; Terruzzi E; Mussetti A; Pini M; Bosi A; Dominietto A; Cascavilla N; Onida F; Narni F; Farina L; Rambaldi A; Corradini P
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1102-1109. PubMed ID: 28390983
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
12. [Allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia].
Wang Y; Liu KY; Xu LP; Liu DH; Chen H; Han W; Chen YH; Shi HX; Zhang YC; Wang JZ; Zhang XU; Chen Y; Huang XJ; Lu DP
Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):903-6. PubMed ID: 18261271
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma.
Laudi N; Arora M; Burns L; McGlave P; Miller J; Bohac G; Rogers T; Barker J; Coad J; Weisdorf D
Am J Hematol; 2006 Jul; 81(7):519-24. PubMed ID: 16755570
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research.
Hamadani M; Saber W; Ahn KW; Carreras J; Cairo MS; Fenske TS; Gale RP; Gibson J; Hale GA; Hari PN; Hsu JW; Inwards DJ; Kamble RT; Klein A; Maharaj D; Marks DI; Rizzieri DA; Savani BN; Schouten HC; Waller EK; Wirk B; Lazarus HM
Biol Blood Marrow Transplant; 2013 Apr; 19(4):625-31. PubMed ID: 23333532
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
[TBL] [Abstract][Full Text] [Related]
16. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation.
Chen RW; Palmer JM; Tomassetti S; Popplewell LL; Alluin J; Chomchan P; Nademanee AP; Siddiqi T; Tsai NC; Chen L; Zuo F; Abary R; Cai JL; Herrera AF; Rossi JJ; Rosen ST; Forman SJ; Kwak LW; Holmberg LA
J Hematol Oncol; 2018 Jun; 11(1):87. PubMed ID: 29954415
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience.
Kawada H; Yoshimitsu M; Nakamura D; Arai A; Hayashida M; Kamada Y; Maekawa K; Fujino S; Arima M; Arima N; Tabuchi T; Inoue H; Hamda H; Suzuki S; Matsushita K; Arima N
Biol Blood Marrow Transplant; 2015 Apr; 21(4):696-700. PubMed ID: 25542158
[TBL] [Abstract][Full Text] [Related]
18. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
19. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
[TBL] [Abstract][Full Text] [Related]
20. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]